Eli Lilly Leads a Health Care Rally as Investors Flee Tech After Hot Inflation Data

While the Nasdaq fell nearly 2%, drugmakers had one of their best days in months, a textbook case of sector rotation.

On a rough day for the stock market, one corner stood out. Health care stocks rose about 2.4% on Wednesday, Oct. 14, making it the best-performing sector in the S&P 500, according to TheStreet. Eli Lilly, the world's most valuable drugmaker, led the way with a gain of about 4.1% to $1,214, the best performance in the S&P 500 that day, according to a Dow Jones report published by Tiger Brokers.

Who rose

The rally was broad. Merck climbed about 3.7% to $147.29, AbbVie gained about 3.5% to $283.86, close to a record closing high, and UnitedHealth Group added about 2.9%. Bristol Myers Squibb, Pfizer, Amgen and AstraZeneca also rose, with several large drugmakers up roughly 4% at midday. Consumer staples, companies that sell everyday necessities like food and household goods, were close behind, up about 2.2%.

Meanwhile, technology stocks fell 3%, and the Nasdaq dropped 1.88%.

Why investors moved into health care

The trigger was September's inflation report, which showed consumer prices up 3.7% from a year earlier, hotter than expected. That raised the odds that the Federal Reserve will raise interest rates again and pushed Treasury yields higher. Fast-growing tech companies tend to suffer most when rates rise, so investors pulled money out of them.

Much of that money went into "defensive" sectors. These are industries whose sales tend to hold up whether the economy is booming or slowing, because people need medicine, groceries and toothpaste no matter what. Moving money from one part of the market to another this way is called sector rotation. Dow Jones noted that the health care gains weren't driven by a single company announcement but by investors seeking safety after the inflation report.

Lilly also had company news. It announced a collaboration with Prelude Therapeutics to test Prelude's experimental breast cancer drug alongside two Lilly cancer medicines in an early-stage trial, and Bank of America reiterated its buy rating with a $1,341 price target, according to Investing.com. Lilly reports third-quarter earnings on Oct. 29, when investors will be watching sales of its weight-loss and diabetes drugs.

What this means for your wallet

Days like Wednesday show why diversification across sectors matters. A portfolio heavy in tech would have taken a hit, while one that also held health care and consumer staples would have held up better. Broad index funds spread your money across all of these sectors automatically.

It's also a reminder not to chase yesterday's winners. Rotations can reverse quickly, and a sector that leads one day can lag the next. If you want more defensive exposure, consider whether it fits your long-term plan rather than reacting to a single day's move.

For many people, the simplest approach is a mix of broad stock and bond funds matched to their goals and timeline, adjusted once or twice a year rather than after every headline.

This article is for education only and is not financial advice. Everyone's situation is different.